Atlas Venture Associates Opportunity I, L.P.
CIK 1780065 · last filed 2024-02-09
Atlas Venture Associates Opportunity I, L.P. is a corporate insider who has filed 3 SEC Form 4 insider transactions across 2 companies since 2019. The most recent filing shows the insider sold $3.8K of XLO on Feb 9, 2024. Across all open-market trades the lifetime net is +$25.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $22.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$22.89M
2
3
$25.89M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| XLO | 10%+ Owner | 2,754,109 | $8.31 | $22.89M | -$25.4K | 2 | 2024-02-09 |
| Akero Therapeutics, Inc. (AKRO) Delisted | 10%+ Owner | 505,099 | $54.65 | $27.60M | $25.92M | 1 | 2019-06-25 |
Recent Filings
3 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-02-09 | XLO | Sell (S) | −6,000 | -$3.8K | EDGAR |
| 2024-01-16 | XLO | Sell (S) | −25,410 | -$21.6K | EDGAR |
| 2019-06-25 | Akero Therapeutics, Inc. (AKRO) Delisted | Mixed | +23,849,148 | $25.92M | EDGAR |